Physician profile
Mark I Miller
NPI 1144219791
$13,669.79
in general payments reported to CMS, 2019-2025
47 companies · $1,310 in 2025
The $1,310 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,794 · 2020: $6,132 · 2021: $1,182 · 2022: $758 · 2023: $594 · 2024: $900 · 2025: $1,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,725 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,724.83 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $5,702.38 | 2019-2025 | Xtandi |
| Metuchen Pharmaceuticals | $2,556.83 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $677.68 | 2021-2025 | Prolaris |
| Antares Pharma, INC. | $657.29 | 2022-2025 | Xyosted |
| Endo Pharmaceuticals INC. | $375.78 | 2019-2021 | |
| Janssen Biotech, INC. | $336.96 | 2019-2025 | Erleada |
| Boston Scientific Corporation | $323.69 | 2022-2025 | Spaceoar System, Spaceoar Vue System - 10ml |
| Medtronic, INC. | $254.68 | 2021-2025 | Interstim |
| Bayer Healthcare Pharmaceuticals INC. | $246.48 | 2019-2024 | |
| Tolmar, INC. | $223.34 | 2023-2025 | Eligard |
| Dendreon Pharmaceuticals LLC | $171.69 | 2019-2025 | Provenge |
| Pfizer INC. | $166.92 | 2019-2025 | |
| Myovant Sciences INC. | $159.45 | 2021-2022 | |
| Olympus America INC. | $158.34 | 2025 | Itind System |
| Teleflex LLC | $149.99 | 2021-2025 | Urolift |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $140.66 | 2020-2022 | |
| 180 Medical, INC. | $119.17 | 2019-2025 | |
| Urogen Pharma, INC. | $105.83 | 2021-2025 | |
| Allergan, INC. | $94.34 | 2019-2022 | |
| Acerus Pharmaceuticals Corporation | $92.47 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $88.58 | 2020-2025 | Imfinzi, Calquence |
| Seagen INC. | $78.99 | 2025 | |
| Verity Pharmaceuticals INC. | $66.76 | 2025 | Trelstar |
| Progenics Pharmaceuticals, INC. | $63.41 | 2023-2025 | Pylarify |
| Tempus Ai, INC | $63.20 | 2024-2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $62.41 | 2021-2025 | Lynparza |
| Cook Medical LLC | $58.79 | 2024-2025 | Litho 150, S~Curve |
| Aytu Biopharma, INC. | $49.33 | 2019-2020 | |
| Medtronic USA, INC. | $46.97 | 2019-2020 | |
| Urovant Sciences INC | $41.80 | 2021-2022 | |
| Amgen INC. | $40.37 | 2020-2021 | |
| Coloplast Corp | $31.58 | 2024 | |
| Endo USA, INC. | $29.39 | 2025 | Aveed, Xiaflex |
| Mission Pharmacal Company | $29.09 | 2021-2023 | |
| Hollister Incorporated | $25.50 | 2021 | |
| Calyxo, INC. | $22.53 | 2024 | Cvac Aspiration System |
| Mimedx Group, INC. | $21.51 | 2024 | |
| Sumitomo Pharma America, INC. | $18.71 | 2025 | Gemtesa |
| Bioprotect Medical, INC. | $18.14 | 2025 | Bioprotect Balloon Implant System |
| Genzyme Corporation | $17.49 | 2021 | |
| Telix Pharmaceuticals | $15.34 | 2025 | Illuccix |
| Novartis Pharmaceuticals Corporation | $14.21 | 2023 | |
| Abbvie INC. | $14.10 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $13.29 | 2022 | |
| Palette Life Sciences, INC. | $12.73 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.